Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety of Vedolizumab in UC and CD
NCT00619489Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Dec 2007
- Primary completion
- Mar 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Millennium Pharmaceuticals. Started Dec 2007; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT00619489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00619489.